Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt 0.72
CORT's Cash to Debt is ranked higher than
52% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CORT: 0.72 )
CORT' s 10-Year Cash to Debt Range
Min: 0.72   Max: No Debt
Current: 0.72

Equity to Asset -0.10
CORT's Equity to Asset is ranked lower than
51% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CORT: -0.10 )
CORT' s 10-Year Equity to Asset Range
Min: -0.1   Max: 0.9
Current: -0.1

-0.1
0.9
F-Score: 2
Z-Score: -4.08
M-Score: -1.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -104.02
CORT's Operating margin (%) is ranked higher than
71% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CORT: -104.02 )
CORT' s 10-Year Operating margin (%) Range
Min: -69827.59   Max: -104.02
Current: -104.02

-69827.59
-104.02
Net-margin (%) -118.19
CORT's Net-margin (%) is ranked higher than
69% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CORT: -118.19 )
CORT' s 10-Year Net-margin (%) Range
Min: -69537.93   Max: -118.2
Current: -118.19

-69537.93
-118.2
ROE (%) -538.58
CORT's ROE (%) is ranked lower than
54% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CORT: -538.58 )
CORT' s 10-Year ROE (%) Range
Min: -8507.59   Max: -55.4
Current: -538.58

-8507.59
-55.4
ROA (%) -67.61
CORT's ROA (%) is ranked higher than
56% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CORT: -67.61 )
CORT' s 10-Year ROA (%) Range
Min: -124.18   Max: -51.57
Current: -67.61

-124.18
-51.57
ROC (Joel Greenblatt) (%) -2810.34
CORT's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CORT: -2810.34 )
CORT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -391957.14   Max: -2412.14
Current: -2810.34

-391957.14
-2412.14
EBITDA Growth (3Y)(%) -11.50
CORT's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CORT: -11.50 )
CORT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 2.6
Current: -11.5

0
2.6
EPS Growth (3Y)(%) -7.40
CORT's EPS Growth (3Y)(%) is ranked higher than
75% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CORT: -7.40 )
CORT' s 10-Year EPS Growth (3Y)(%) Range
Min: -31.3   Max: 6.6
Current: -7.4

-31.3
6.6
» CORT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CORT Guru Trades in Q2 2013

Steven Cohen 450,000 sh (New)
Jean-Marie Eveillard 2,536,866 sh (unchged)
» More
Q3 2013

CORT Guru Trades in Q3 2013

Steven Cohen 500,000 sh (+11.11%)
Jean-Marie Eveillard 2,496,078 sh (-1.61%)
» More
Q4 2013

CORT Guru Trades in Q4 2013

Steven Cohen Sold Out
Jean-Marie Eveillard 991,978 sh (-60.26%)
» More
Q1 2014

CORT Guru Trades in Q1 2014

Steven Cohen 14,329 sh (New)
Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CORT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 24.04
CORT's P/S is ranked higher than
59% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CORT: 24.04 )
CORT' s 10-Year P/S Range
Min: 11.12   Max: 615
Current: 24.04

11.12
615
Current Ratio 2.23
CORT's Current Ratio is ranked higher than
60% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CORT: 2.23 )
CORT' s 10-Year Current Ratio Range
Min: 2.23   Max: 20.96
Current: 2.23

2.23
20.96
Quick Ratio 2.14
CORT's Quick Ratio is ranked higher than
62% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CORT: 2.14 )
CORT' s 10-Year Quick Ratio Range
Min: 2.14   Max: 20.96
Current: 2.14

2.14
20.96
Days Inventory 462.00
CORT's Days Inventory is ranked higher than
77% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CORT: 462.00 )
CORT' s 10-Year Days Inventory Range
Min: 476.53   Max: 2487.36
Current: 462

476.53
2487.36
Days Sales Outstanding 45.83
CORT's Days Sales Outstanding is ranked higher than
88% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CORT: 45.83 )
CORT' s 10-Year Days Sales Outstanding Range
Min: 45.83   Max: 61.48
Current: 45.83

45.83
61.48

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.10
CORT's Price/Median PS Value is ranked higher than
100% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. CORT: 0.10 )
CORT' s 10-Year Price/Median PS Value Range
Min: 0.06   Max: 1.69
Current: 0.1

0.06
1.69
Earnings Yield (Greenblatt) -4.30
CORT's Earnings Yield (Greenblatt) is ranked higher than
71% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CORT: -4.30 )
CORT' s 10-Year Earnings Yield (Greenblatt) Range
Min: -11   Max: 3588.9
Current: -4.3

-11
3588.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HTD.Germany,
Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical Company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Two Stocks for the Value Investor and GAARP Enthusiast Jun 07 2014 
Corcept Therapeutics Inc. Reports Operating Results (10-K/A) Aug 19 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 16 2010 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Nov 12 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) Aug 11 2009 
Corcept Therapeutics Inc. Reports Operating Results (10-Q) May 13 2009 


More From Other Websites
Nasdaq stocks posting largest percentage increases Apr 24 2015
Coverage initiated on Corcept Therapeutics by FBR Capital Apr 21 2015
Corcept Therapeutics (CORT) Looks Good: Stock Up 83.9% - Tale of the Tape Apr 09 2015
Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council Apr 08 2015
Cortendo AB Joins National Organization for Rare Disorders (NORD)® Corporate Council Apr 08 2015
CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure Apr 02 2015
Corcept's Warrants Exercised, Invest in Korlym, Pipeline - Analyst Blog Apr 02 2015
Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support... Apr 01 2015
Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support... Apr 01 2015
Cortendo AB Announces Appointments of A. Brian Davis as Chief Financial Officer and Stephen Long as... Mar 23 2015
Interim report for the fourth quarter and full year 2014 Mar 23 2015
CORCEPT THERAPEUTICS INC Financials Mar 20 2015
Cortendo to Present at Upcoming Investor Conferences Mar 19 2015
Cortendo to Join Patients, Families and Pennsylvania Legislators to Raise Awareness for Rare... Mar 19 2015
Cortendo Announces Notice of Extraordinary General Meeting Mar 19 2015
Cortendo AB Names John H. Johnson as Chairman and Appoints Richard Kollender as Director Mar 19 2015
Cortendo Announces Proposed Changes to Board of Directors Mar 19 2015
CORCEPT THERAPEUTICS INC Files SEC form 10-K, Annual Report Mar 13 2015
Corcept Therapeutics (CORT) Jumps: Stock Rises 14.5% - Tale of the Tape Mar 12 2015
Corcept Therapeutics Announces 2014 Financial Results and Provides Clinical Update Mar 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK